Experts Question CDC’s Muted Role in Cruise-Ship Hantavirus Outbreak: A hantavirus outbreak aboard the MV Hondius has raised concerns about the CDC’s weakened international response capacity. After several passengers became ill and three died, the WHO moved quickly to classify the situation as an outbreak and assess the broader risk, while U.S. officials were slower to deploy teams, brief doctors, or communicate publicly. Experts including Lawrence Gostin, Jennifer Nuzzo, Jeanne Marrazzo, and former CDC director Tom Frieden contrasted the agency’s muted response with its more visible role during the Diamond Princess COVID-19 outbreak. The CDC later sent teams to the Canary Islands and Nebraska, issued a health alert, and said public risk remained extremely low. Critics argue the episode reflects deeper damage from staffing cuts, WHO withdrawal, and reduced global coordination. (AP)

More Hantavirus Cases Emerge After Cruise-Ship Evacuation: A French woman and an American passenger tested positive for hantavirus after evacuation from the MV Hondius, the cruise ship at the center of what WHO officials described as the first known hantavirus outbreak aboard a cruise vessel. Passengers were flown out of Spain’s Canary Islands on military and government planes, with many countries placing evacuees under quarantine or medical observation. Three passengers have died since the outbreak began, and six infections have been reported. One of 17 Americans flown to Nebraska tested positive without symptoms, while another had mild symptoms. Health officials continue to say the public risk is low because hantavirus usually spreads from rodent droppings, though the Andes virus strain can rarely spread between people. (AP)

Largest Blood-Protein Genetics Map Points to New Drug Targets: A massive proteogenomic study has tied human genetic variation to blood-protein levels at unprecedented scale, offering a more direct bridge between disease-associated DNA signals and biological mechanisms. Led by Queen Mary University of London and BIH at Charité, the project combined data from more than 78,000 participants across 38 cohorts and involved 118 investigators from 89 institutions. The goal was not simply to catalog protein variation, but to connect genetic regulation, disease biology, and possible drug opportunities. One example highlighted by the researchers is evidence that TYK2 inhibitors, already used for psoriasis, may have potential in rheumatoid arthritis. The study underscores how large multiomic datasets can move genetics closer to therapeutic decision-making. (EurekAlert!)

A Watermelon Super-Pangenome for Precision Breeding: Researchers have built a watermelon “super-pangenome” that captures genetic diversity across all seven living species in the watermelon genus, rather than relying on one reference genome. The Nature Genetics study integrated 138 wild and cultivated genomes, creating a graph-based resource able to detect structural variants that ordinary SNP-centered approaches can miss. That matters because domestication has narrowed the diversity of commercial watermelon, potentially weakening its resilience to pests, disease, and climate stress. The team linked one structural variant to flesh color intensity, a market and nutrition trait, and developed predictive models using high-impact SNP and structural-variant markers. The work turns watermelon diversity into a practical breeding map for future cultivars. (EurekAlert!)

Single-Cell Immune Map Reveals Sex-Based Genetic Differences: A new American Journal of Human Genetics study uses single-cell analysis to probe why autoimmune diseases disproportionately affect women. Researchers from the Garvan Institute and UNSW Sydney analyzed more than one million immune cells, grouping them by gene-expression patterns and immune function. The work found sex-linked differences that had been hidden in bulk immune measurements, offering a sharper view of how male and female immune systems may diverge at the cellular and genetic level. The findings are especially relevant to lupus, which can affect up to nine women for every one man. Rather than treating sex as a simple demographic variable, the study suggests it may shape immune-cell behavior in clinically meaningful ways. (EurekAlert!)

CRISPR Cas12a2 Turns Gene Targeting Into Cell Destruction: A Nature study describes a CRISPR system designed not to edit DNA, but to kill selected cells. The technology uses Cas12a2, a CRISPR-associated protein that recognizes a programmable RNA target. Once activated, Cas12a2 does not make a neat edit like Cas9; it shreds DNA broadly enough to trigger cell death. Researchers programmed the system to target virus-infected or cancer-like cells in lab experiments while sparing healthy cells. The approach remains early and has mostly been tested in cells in dishes, but it opens a provocative therapeutic direction: using genetic or transcriptional signatures to eliminate harmful cells outright. If it can be controlled in organisms, it could become a powerful research and medical tool. (EurekAlert!)

AI-Assisted RNA-Seq Alignment Gets a Splice-Site Upgrade: Genome Biology published DeepSAP, a new RNA-seq alignment method that combines transcriptome-guided genomic alignment with transformer-based scoring of splice junctions. RNA-seq remains difficult because reads can span complex splice sites, map to multiple locations, or reflect chimeric events. DeepSAP is designed to improve detection of splice junctions, indels, and difficult splicing patterns by integrating GSNAP with deep-learning models trained around donor and acceptor sites. In the Baruzzo human simulated benchmark, the authors report the highest mean F1 score for splice-junction detection compared with DRAGEN, novoSplice, STAR, HISAT2, and Subjunc. The result is technical, but important: better alignment can sharpen gene-expression and splicing studies across biology and medicine. (Springer)

LINE1 RNA Chemistry May Make Cancer Cells More Vulnerable: A new Genome Biology paper links RNA modification on LINE1 elements to cancer-cell resistance against PARP inhibitors. PARP inhibitors can be effective cancer drugs, but resistance remains a major clinical obstacle. The study reports that m6A modification of LINE1 RNA helps cancer cells repair DNA damage. Removing those modifications, or disrupting METTL3, increased chromatin marks associated with reduced accessibility, impaired homologous recombination repair, and made both BRCA-mutant and BRCA-wild-type cells more sensitive to olaparib. The proposed therapeutic implication is combination treatment: targeting METTL3 or LINE1 RNA methylation alongside PARP inhibition. The study adds another layer to cancer genomics by showing how repetitive-element RNA chemistry can shape DNA repair and drug response. (Springer)

Gene Therapy’s Breakthrough Moment in Inherited Blindness: Scientific American revisits Luxturna, the gene-augmentation therapy that helped prove inherited disease could be treated by delivering working genetic instructions. The article centers on Katherine High, Jean Bennett, and Albert Maguire, three 2026 Breakthrough Prize honorees whose work helped move the therapy from lab studies to dogs and then human trials. Luxturna treats certain inherited retinal diseases, including forms of Leber’s congenital amaurosis, by targeting a molecular defect in light-sensitive retinal cells. In patients, the therapy increased visual sensitivity more than 40,000-fold, according to the article. Beyond the emotional power of restored sight, the story shows how one rare-disease therapy helped establish a broader framework for genetic medicine. (Scientific American)

The Gene Switch Behind Sickle Cell Therapy’s Breakthrough: Another Scientific American Breakthrough Prize feature focuses on BCL11A, a gene whose suppression can reactivate fetal hemoglobin and transform treatment for sickle cell disease and beta-thalassemia. Researchers Swee Lay Thein and Stuart Orkin were honored for work showing that turning off BCL11A could restore healthy hemoglobin production. That insight became the foundation for gene therapies now showing dramatic clinical effects: sickle cell patients in trials experienced resolution of pain crises during the study period, while beta-thalassemia patients no longer needed transfusions or bone marrow transplants. The story is both a genetics detective tale and an access problem, since the next challenge is making curative therapies available beyond elite medical centers. (Scientific American)

Shepherd’s Purse Genomes Reveal Climate-Linked Adaptation: A population-genomics study of Capsella bursa-pastoris, or shepherd’s purse, examined how a widespread polyploid plant adapts across altitude. Researchers sampled 40 individuals from 14 Chinese populations spanning eastern lowlands and western highlands, then used whole-genome resequencing to identify two genetic lineages corresponding to altitude. Genome scans found 54 candidate genes under positive selection, including genes tied to energy metabolism, photosynthesis, signaling, growth regulation, and membrane transport. Climate variables explained 12.7% of genetic variation, more than geography or population structure, pointing to temperature seasonality and precipitation as important drivers. The findings are useful beyond one weed species: they show how landscape genomics can help predict plant resilience under changing climates. (EurekAlert!)

Genetically Engineered Chickens as Medicine Factories: The Scientist reports on Neion Bio’s attempt to turn chicken eggs into low-cost bioreactors for biologic medicines. The company uses genetically engineered chickens to produce therapeutic proteins in eggs, aiming to reduce the cost and complexity of manufacturing biologics. Traditional biologics production relies heavily on expensive cell-culture infrastructure, especially mammalian systems such as CHO cells. Neion Bio’s premise is that the egg is already a high-output, self-contained protein-production vessel, and genetic engineering can redirect that capacity toward medical proteins. The approach is still a company platform rather than a proven replacement for established biomanufacturing, but it is an intriguing convergence of synthetic biology, animal biotechnology, and drug-access economics. (The Scientist)

Fathers’ Lifestyles May Leave Molecular Marks in Sperm: A growing body of research suggests sperm may carry more than DNA. Studies in mice show that exercise, diet, stress, alcohol, and environmental exposures can alter small RNA fragments in sperm, with effects appearing in offspring metabolism, development, behavior, and fitness. One 2025 study found that microRNAs from exercising male mice could produce fitter offspring even when injected into unrelated embryos. Researchers now suspect sperm acquire many of these RNAs while passing through the epididymis, via RNA-carrying vesicles called epididymosomes. Skeptics remain, especially over whether tiny sperm RNA doses can influence much larger eggs. But recent studies suggest paternal RNA fragments do enter embryos and may alter gene activity at natural sperm-level doses, broadening responsibility for preconception health beyond mothers alone. (Ars Technica)